Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 6, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for October 1, 2006 Subscribe to this News Feed      
 

Fentanyl Patch Developed by Labtec GmbH First Generic to be Approved for Marketing in Canada

Labtec´s licensee ratiopharm started marketing in Canada a transdermal patch containing fentanyl for treatment of strong chronic pain, which is generic to J&J´s blockbuster Durogesic®. The patch is 1/3 smaller than the originator´s product and is the first generic fentanyl patch to be approved for marketing in Canada.

(PRWEB) October 1, 2006 -- Last month ratiopharm Canada launched “ratio-FENTANYL Matrix System“, a product generic to Johnson&Johnson´s Durogesic®, which in 2004 generated global revenues of over $2 billion US. The product is the first generic fentanyl patch to be approved in Canada and was developed by Germany-based Labtec GmbH, who licensed it to ratiopharm for Europe and Canada. Besides Canada, the product is already approved in Germany, Austria and The Netherlands. ratiopharm is expecting approval for all other countries of their territory within the next months. Outside Europe and Canada, Labtec has licensed the product for USA, Australia, Israel and Turkey to leading national companies.

The patch uses Labtec´s innovative matrix technology, making it the smallest fentanyl patch on the market. Because of its small size the product is more convenient for patients who suffer from strong chronic pain and have to wear the patch for three days before replacing it with a new one.

Labtec is now actively seeking to license the product to Latin America, Africa, Near East, South Asia and East Asia/Pacific.

Labtec GmbH (www.labtec-pharma.com) is a leading drug delivery company specialised on development of matrix-type transdermal and topical patches as well as fast dissolving oral films (Rapidfilms).

ratiopharm (www.ratiopharm.ca) is third among Canadian generic drug companies. It employs 400 people in its Mirabel and Mississauga facilities and boasts annual sales approaching $300 million.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RmFsdS1Mb3ZlLVRoaXItU3VtbS1JbnNlLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Ingo Lehrke
LABTEC GMBH
+49 2173 97350
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright